abstract |
The present invention relates to a pharmaceutical composition comprising a lipase inhibitor, preferably orlistat, having a melting point of ≥37 ° C, a sucrose fatty acid ester, wherein the sucrose fatty acid ester is a mono-, di-, tri- or tetra-ester, and optionally one or more pharmaceutically acceptable excipients. |